All In Biotech

Drug Trial Radar · NCT05361005

Tolerability and Safety of BDB-001 Injection in Healthy Subjects

A Phase Ic Single Center, Randomized, Double-Blind, Placebo-controlled, Single Dose Escalation and Multiple Dose Study to Evaluate the Tolerability and Pharmacokinetics of BDB-001 Injection in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: May 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

Mar 12, 2020

Primary completion

May 8, 2020

Study completion May 8, 2020

Sponsor

Sponsor type
Industry
Collaborators
Beijing Defengrei Biotechnology Co.,Ltd
First posted
May 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A clinical study to evaluate the tolerability, PK and PD characteristics of BDB-001 Injection in healthy subjects.

Conditions

  • Healthy

Interventions

  • BDB-001 injectionDrug

    Intravenous injection

  • PlaceboDrug

    Intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities And Clinically Significant Physical Examination AbnormalitiesTime frame: Up to 28 Days
  2. Maximum plasma concentration (Cmax)Time frame: Up to 504 hours postdose
  3. Area under the plasma concentration-time curve from time 0 to infinity (AUC0inf)Time frame: Up to 504 hours postdose
  4. Area under the plasma concentration-time curve from time 0 to 480hr(AUC00-480hr)Time frame: Up to 504 hours postdose
  5. Time of maximum concentration (Tmax)Time frame: Up to 504 hours postdose
  6. Elimination half-life (t1/2)Time frame: Up to 504 hours postdose
  7. Clearance (CL)Time frame: Up to 504 hours postdose
  8. Apparent volume of distribution (Vz)Time frame: Up to 504 hours postdose
  9. Mean residence time (MRT)Time frame: Up to 504 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shu Lan (Hangzhou) Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.